EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer

Huayan Huang,Xiaokuan Zhu,Yongfeng Yu,Ziming Li,Yi Yang,Liliang Xia,Shun Lu
DOI: https://doi.org/10.1186/s12967-024-05456-5
IF: 8.44
2024-07-16
Journal of Translational Medicine
Abstract:Non-small cell lung cancer (NSCLC) patients with EGFR mutations exhibit an unfavorable response to immune checkpoint inhibitor (ICI) monotherapy, and their tumor microenvironment (TME) is usually immunosuppressed. TGF-β plays an important role in immunosuppression; however, the effects of TGF-β on the TME and the efficacy of anti-PD-1 immunotherapy against EGFR -mutated tumors remain unclear.
medicine, research & experimental
What problem does this paper attempt to address?